K. Menear

发表

Purification and characterization of human Syk produced using a baculovirus expression system.

D. Baldock, B. Graham, P. Graff, 2000, Protein expression and purification.

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

N. Curtin, I. Hardcastle, R. Griffin, 2007, Journal of medicinal chemistry.

8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).

N. Curtin, I. Hardcastle, R. Griffin, 2008, Bioorganic & medicinal chemistry letters.

An intramolecular Diels–Alder approach to forskolin

P. R. Jenkins, K. Menear, P. Barraclough, 1984 .

Syk-deficient eosinophils show normal interleukin-5-mediated differentiation, maturation, and survival but no longer respond to FcgammaR activation.

V. Tybulewicz, E. Schweighoffer, C. Walker, 2000, Blood.

Magnetic size determination for interacting fine particle systems

R. Chantrell, K. O'Grady, K. Menear, 1984 .

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Lisa L. Smith, I. Hickson, G. Smith, 2009, Bioorganic & medicinal chemistry letters.

Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.

I. Hickson, G. Smith, G. Hermann, 2009, Bioorganic & medicinal chemistry letters.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Lisa L. Smith, C. Chresta, S. Guichard, 2010, Cancer research.

Studies on the uptake of low molecular weight monomeric tris-galactosyl conjugates by the rat liver.

H. Eichler, P. Taylor, J. Hastewell, 1992, Biochemical pharmacology.

The discovery of orally available thrombin inhibitors: studies towards the optimisation of CGH1668.

D. Janus, K. Menear, David J. Farr, 1998, Bioorganic & medicinal chemistry letters.

Studies towards the identification of potent, selective and bioavailable thrombin inhibitors.

D. Janus, K. Menear, D. Bentley, 1999, Bioorganic & medicinal chemistry letters.

Studies Towards the Identification of Potent, Selective and Bioavailable Thrombin Inhibitors

K. Menear, 1999 .

Progress towards the discovery of orally active thrombin inhibitors.

K. Menear, 1998, Current medicinal chemistry.

Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.

Krystyna J. Dillon, N. Martin, G. Smith, 2006, Bioorganic & medicinal chemistry letters.

Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase.

N. Martin, G. Smith, K. Menear, 2008, Bioorganic & medicinal chemistry letters.

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

A. Lau, M. O’Connor, C. Knights, 2008, Journal of medicinal chemistry.

Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.

Krystyna J. Dillon, N. Martin, G. Smith, 2005, Bioorganic & medicinal chemistry letters.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Linette Ruston, M. Hummersone, K. Pike, 2013, Bioorganic & medicinal chemistry letters.

Direct thrombin inhibitors: current status and future prospects.

K Menear, K. Menear, 1999, Expert opinion on investigational drugs.

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

K. Valerie, M. O’Connor, L. Povirk, 2009, Molecular Cancer Therapeutics.

The design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors.

K. Menear, X. Cockcroft, M. Tweed, 2000, Bioorganic & medicinal chemistry letters.

DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

G. L. Young, I. Hardcastle, R. Griffin, 2011, Bioorganic & medicinal chemistry letters.

The discovery of orally available thrombin inhibitors: optimisation of the P1 pharmacophore.

B. Wathey, D. Janus, K. Menear, 1999, Bioorganic & medicinal chemistry letters.

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

N. Curtin, R. Griffin, Yan Zhao, 2011, Molecular Cancer Therapeutics.

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

N. Curtin, I. Hardcastle, R. Griffin, 2013, Journal of medicinal chemistry.

DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.

N. Curtin, I. Hardcastle, R. Griffin, 2010, Journal of medicinal chemistry.

A novel approach to the site specific delivery of potential HMG-CoA reductase inhibitors

P. Taylor, C. Howes, K. Menear, 1992 .

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Linette Ruston, M. Hummersone, K. Pike, 2013, Bioorganic & medicinal chemistry letters.

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Lisa L. Smith, I. Hickson, G. Smith, 2009, Bioorganic & medicinal chemistry letters.

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

N. Curtin, R. Griffin, Yan Zhao, 2012, Molecular Cancer Therapeutics.

Optimisation of the P2 pharmacophore in a series of thrombin inhibitors: ion-dipole interactions with lysine 60G.

M. Grütter, J. Priestle, B. Wathey, 1999, Bioorganic & Medicinal Chemistry Letters.

DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

I. Hardcastle, R. Griffin, B. Golding, 2011, Bioorganic & medicinal chemistry letters.